Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were takin Wegovy ...
The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...
Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe ...
Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...
The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...
While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...
Achondroplasia, which affects around one in 20,000 babies, has just one approved treatment: BioMarin’s Voxzogo. However, new investigational treatments are vying to compete in the area.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback